NASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $81.00 -2.98 (-3.54%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Monopar Therapeutics Stock (NASDAQ:MNPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Monopar Therapeutics alerts:Sign Up Key Stats Today's Range$80.95▼$84.0450-Day Range$77.97▼$123.8452-Week Range$50.07▼$124.82Volume61,048 shsAverage Volume209,765 shsMarket Capitalization$543.70 millionP/E RatioN/ADividend YieldN/APrice Target$122.00Consensus RatingModerate Buy Company Overview Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies. Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers. These programs include radiopharmaceutical applications intended to help identify or treat tumors expressing uPAR. Monopar was founded in 2014 and is headquartered in Wilmette, Illinois. Its activities are primarily focused on clinical development and collaborations within the oncology and radiopharmaceutical sectors, with potential applications for patients in the United States and other international markets. Chandler Robinson has served as the company’s chief executive officer and has been involved in its development since its early stages.AI Generated. May Contain Errors. Read More Monopar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreMNPR MarketRank™: Monopar Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 373rd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMonopar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMonopar Therapeutics has a consensus price target of $122.00, representing about 48.3% upside from its current price of $82.26.Amount of Analyst CoverageMonopar Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Monopar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($2.98) to ($4.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -37.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -37.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Monopar Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.93% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 0.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentMonopar Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Monopar Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for MNPR on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,023,094.00 in company stock.Percentage Held by Insiders9.70% of the stock of Monopar Therapeutics is held by insiders.Percentage Held by Institutions1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Stock News HeadlinesMonopar Therapeutics (NASDAQ:MNPR) Stock: Insider Christopher Starr Sells 8,400 SharesOctober 7 at 4:22 AM | americanbankingnews.comMonopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC FilingOctober 5, 2026 | marketscreener.comMThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)Monopar CEO sells 29,056 shares under planOctober 1, 2026 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Price Down 5.3% Following Insider SellingOctober 1, 2026 | americanbankingnews.comPiper Sandler Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)September 29, 2026 | theglobeandmail.comMonopar Therapeutics (NASDAQ:MNPR) CEO Chandler Robinson Sells 29,056 Shares of Company StockSeptember 29, 2026 | insidertrades.comMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026August 19, 2026 | markets.businessinsider.comSee More Headlines MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $65.30 on January 1st, 2026. Since then, MNPR shares have increased by 26.0% and is now trading at $82.2550. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. When did Monopar Therapeutics' stock split? Monopar Therapeutics shares reverse split on the morning of Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Gold.com (GOLD), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/12/2026Today10/09/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (23m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MNPR's financial health is in the Green zone, according to TradeSmith. MNPR has been in this zone for over 23 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MNPR CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees22Year Founded2014Price Target and Rating Average Price Target for Monopar Therapeutics$122.00 High Price Target$145.00 Low Price Target$100.00 Potential Upside/Downside+50.6%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-13.08% Return on Assets-12.79% Debt Debt-to-Equity RatioN/A Current Ratio33.56 Quick Ratio33.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.62 per share Price / Book3.93Miscellaneous Outstanding Shares6,712,000Free Float6,061,000Market Cap$543.70 million OptionableNot Optionable Beta1.50 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MNPR) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts